Alliance Growers Corp. (CSE:ACG) (FSE: 1LA) (WKN: A2DFYX) (OTC: ALGWF) (“Alliance Growers” or the “Company”) is pleased to announce the completion of the pre-construction phase of the Cannabis Biotech Centre, the primary facility of the Cannabis Biotech Complex, being developed in Deroche, BC, Canada, near Mission BC. As previously announced, Alliance Growers has entered into a partnership with WFS Pharmagreen Inc., a wholly owned Canadian subsidiary of Pharmagreen Biotech, Inc. (OTC:PHBI.PK) (“Pharmagreen”) to develop the Cannabis Biotech Complex.
Pharmagreen, a cannabis biotech company focused on producing cannabis starter plantlets through its proprietary tissue culture process, is currently completing its pre-construction phase of the Cannabis Biotech Complex. Alliance Growers has committed to acquiring a 30% equity interest and 30% profit share in the Cannabis Biotech Complex, to be carried out in stages. The funds advanced by Alliance Growers to Pharmagreen to date, have been instrumental in completing the pre-construction phase of the project.
Pre-construction is one of the most significant phases of the entire process, it includes completion of building engineering, designs for structural loads, electrical, HVAC and geotechnical as the main components. Pre-construction also includes submission of Health Canada applications for an ACMP and a Dealer’s Licence, both of which were submitted in June 2018.
The Alliance Growers business model integrates with Pharmagreen’s business model. Alliance Growers will focus on the development, investment and acquisition of quality ACMPR applicants to secure supply contracts for tissue culture plantlets and develop both medical and recreational distribution channels for the sale of Alliance Growers and Pharmagreen branded cannabis products. Pharmagreen will focus on tissue culture plantlets and other valuable services for cultivators. Alliance Growers will establish a Canadian retail presence in the adult-use cannabis market via acquisitions or partnerships that have the required experience and expertise. In addition to the partnership with Pharmagreen, to develop the Cannabis Biotech Complex, Alliance Growers made a strategic investment of CAD$300,000 in the equity of Pharmagreen, resulting in 1,200,000 common shares in the capital of Pharmagreen Biotech Inc.
Commenting on the relationship with Pharmagreen, President and CEO of Alliance Growers, Dennis Petke stated “I have been working closely with Peter Wojcik on many fronts in the Cannabis Space since early 2016. Recently, Peter and I presented the Alliance Growers business model at several roadshows in Vancouver, Montreal and Toronto. Peter’s cannabis expertise made a strong positive impression during the presentations, as he is extremely knowledgeable in the areas of cultivation, strain protocols, extraction and distillation, as well as CBD/THC formulations for medical interventions. On a personal level, what I respect and appreciate most about Peter, is his passion for making a difference in peoples lives through the meticulous custom development of cannabis based medical protocols for individuals, while at the same time I admire his drive for developing a state of the art facility to ensure the utmost quality starter plantlets in cannabis cultivation for both medical and recreational purposes. We, at Alliance Growers, look forward to a strong, prosperous and enduring business relationship with Phramagreen for many years to come.”
Commenting on the recent road shows in Vancouver, Montreal and Toronto, with Alliance Growers, Peter Wojcik, CEO of Pharmagreen Biotech Inc., commented “It was a real working session to participate in the Alliance roadshows with Dennis Petke, their CEO to some of the finest brokers, dealers, and fund managers in Canada. They all recognized that the Alliance model has the fundamentals from a plantlet to sale model.”
About Alliance Growers Corp.
Alliance Growers is a Diversified Global Medical Cannabis Company driven by the Company’s ‘Four Pillars’ Organization Plan — Cannabis Biotech Complex, Strategic ACMPR Investments, CBD Oil Supply and Distribution, and Research and Technology.
Alliance Growers is working with Pharmagreen Biotech Inc. advancing a new business partnership, to jointly develop and operate a 62,000-square foot facility, to be the first of its kind in Western Canada to house a DNA Botany lab, extraction facility and Tissue Culture Plantlet Production facility to service the Cannabis market and agriculture market in general. The proposed Cannabis Biotech Complex’s main facility is the Cannabis Biotech Centre which will grow Cannabis plantlets using proprietary tissue culture propagation, specifically utilizing the “Chibafreen Invitro Plant Production System”, which allows for more tissue cultured plantlets to be produced in less space and less time.
About Pharmagreen Biotech, Inc. and WFS Pharmagreen Inc.
WFS Pharmagreen Inc. is a wholly owned Canadian based subsidiary of Pharmagreen Biotech, Inc., a publicly traded (OTC PINKS: PHBI) company. WFS Pharmagreen Inc. is a cannabis company that is becoming the largest producer of cannabis plantlets through a proprietary tissue culture process with opportunity to become one of the largest players globally. Pharmagreen’s mission is to advance the technology of tissue culture science and to provide the highest quality 100% germ free, disease free and all genetically the same plantlets of cannabis and other flora while offering full spectrum DNA testing for plant identification, live genetics preservation using low temperature storage for various cannabis and horticulture plants; extraction of botanical oils mainly CBD oil, and to deliver laboratory based services to the North American Cannabis and agriculture sectors. For further information on the company progress on the construction of a 62,000 square foot “Cannabis Biotech Complex” please visit www.pharmagreen.ca
If you would like to be added to Alliance Growers’ news distribution list, please send your email address to firstname.lastname@example.org.
For more information contact:
CEO, President and Director
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE
FORWARD LOOKING INFORMATION
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, the news release contains forward-looking statements and information relating to Company’s corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company’s ability to carry out its business plan. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.
Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company’s ability to identify and complete additional suitable acquisitions to further the Company’s growth as well as risks associated with the medical marijuana industry in general, such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.
The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.